...
首页> 外文期刊>British Journal of Surgery >Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer†
【24h】

Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer†

机译:意大利胃癌研究组D1和D2切除术治疗胃癌的随机临床试验†

获取原文
获取原文并翻译 | 示例
           

摘要

Background:A randomized clinical trial was performed to compare D1 and D2 gastrectomy in specialized Western centres. This paper reports short-term results.Method:A total of 267 patients with gastric cancer were randomly assigned to either a D1 or a D2 procedure in five specialized centres. Based on the findings of the phase II trial and published phase III trials, a prespecified non-inferiority boundary at 12 per cent difference between groups was set regarding total morbidity.Results:In the intention-to-treat analysis, the overall morbidity rate after D2 and D1 dissections was 17·9 and 12·0 per cent respectively (P = 0·178), with a 95 per cent confidence interval of the difference of 0 to 13·0 per cent, slightly exceeding the prespecified non-inferiority limit. There was a single duodenal stump leak in the D2 arm (0·7 per cent). The postoperative 30-day mortality rate was 3·0 per cent after D1 and 2·2 per cent after D2 gastrectomy (P = 0·722).Conclusion:In specialized centres the rate of complications following D2 dissection is much lower than in published randomized Western trials. D2 dissection, in an appropriate setting, can therefore be considered a safe option for the radical management of gastric cancer in Western patients. Registration number: ISRCTN11154654 (http://www.controlled-trials.com). Copyright © 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
机译:背景:进行了一项随机临床试验,以比较专业西方中心的D1和D2胃切除术。方法:总共267例胃癌患者被随机分配到五个专业中心的D1或D2程序中。根据II期试验和已发表的III期试验的结果,在总发病率之间设定了两组之间的差异为12%的预先确定的非劣效性边界。结果:在意向性治疗分析中,总体发病率D2和D1夹层分别为17·9和12·0%(P = 0·178),置信区间为95%,相差0到13·0%,略高于预先设定的非劣性限制。 D2臂仅有一个十二指肠残端漏气(0·7%)。 D1术后胃30天死亡率为3·0%,D2胃切除术后为2·2%(P = 0·722)。结论:在专科中心,D2解剖后的并发症发生率远低于已发表的文献。西方随机试验。因此,在适当的情况下,D2解剖可被认为是西方患者根治性胃癌的安全选择。注册号:ISRCTN11154654(http://www.control-trials.com)。版权所有©2010英国外科杂志学会。由John Wiley&Sons,Ltd.发布。

著录项

  • 来源
    《British Journal of Surgery》 |2010年第5期|p.643-649|共7页
  • 作者

    M. Degiuli; M. Sasako; A. Ponti;

  • 作者单位

    University Division of General Surgery 1a, Turin, Italy;

    Gastric Cancer Division, National Cancer Centre Hospital, Tokyo, Japan;

    Unit of Epidemiology, Centro Prevenzione Oncologica Piemonte, Hospital San Giovanni Battista, Turin, Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号